These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 2545842

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells.
    Kuppner MC, Hamou MF, Bodmer S, Fontana A, de Tribolet N.
    Int J Cancer; 1988 Oct 15; 42(4):562-7. PubMed ID: 3262591
    [Abstract] [Full Text] [Related]

  • 3. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2.
    Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A.
    J Immunol; 1989 Nov 15; 143(10):3222-9. PubMed ID: 2809198
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers.
    Miescher S, Whiteside TL, de Tribolet N, von Fliedner V.
    J Neurosurg; 1988 Mar 15; 68(3):438-48. PubMed ID: 3257792
    [Abstract] [Full Text] [Related]

  • 6. Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes.
    Kuppner MC, Sawamura Y, Hamou MF, de Tribolet N.
    J Neurosurg; 1990 Apr 15; 72(4):619-25. PubMed ID: 1969467
    [Abstract] [Full Text] [Related]

  • 7. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y, Suzuki Y, Katakura R, Miyagi T, Yamaguchi T, Yoshimoto T, Ebina T.
    Clin Cancer Res; 1997 Apr 15; 3(4):633-43. PubMed ID: 9815731
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells.
    Jin B, Scott JL, Vadas MA, Burns GF.
    Immunology; 1989 Apr 15; 66(4):570-6. PubMed ID: 2541074
    [Abstract] [Full Text] [Related]

  • 14. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
    Espevik T, Figari IS, Ranges GE, Palladino MA.
    J Immunol; 1988 Apr 01; 140(7):2312-6. PubMed ID: 3280680
    [Abstract] [Full Text] [Related]

  • 15. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.
    Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS.
    J Immunol; 1986 Dec 15; 137(12):3855-60. PubMed ID: 2878044
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
    Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD.
    Cancer Res; 1992 Mar 15; 52(6):1386-92. PubMed ID: 1531782
    [Abstract] [Full Text] [Related]

  • 17. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family.
    de Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlüsener H, Seifert JM, Bodmer S, Fontana A, Hofer E.
    EMBO J; 1987 Dec 01; 6(12):3673-7. PubMed ID: 3322813
    [Abstract] [Full Text] [Related]

  • 18. Immunomagnetic separation of infiltrating T lymphocytes from brain tumors.
    Bosnes V, Hirschberg H.
    J Neurosurg; 1989 Aug 01; 71(2):218-23. PubMed ID: 2664096
    [Abstract] [Full Text] [Related]

  • 19. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.
    Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dörries R, Schlingensiepen KH, Brysch W.
    J Neurosurg; 1993 Jun 01; 78(6):944-51. PubMed ID: 8487077
    [Abstract] [Full Text] [Related]

  • 20. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.
    Alleva DG, Burger CJ, Elgert KD.
    J Immunol; 1994 Aug 15; 153(4):1674-86. PubMed ID: 8046239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.